Eyepoint Pharmaceuticals Inc Total Liabilities
Eyepoint Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Eyepoint Pharmaceuticals Inc (EYPT) has total liabilities worth $51.51 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EYPT financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Eyepoint Pharmaceuticals Inc (2000–2024)
Total liabilities of Eyepoint Pharmaceuticals Inc from 2000 to 2024. This chart illustrates how Eyepoint Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Eyepoint Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eyepoint Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yiren Digital Ltd
F:19YA
|
Germany | €5.11 Billion |
|
Globus Maritime Ltd
NASDAQ:GLBS
|
USA | $116.02 Million |
|
EP Manufacturing Bhd
KLSE:7773
|
Malaysia | RM439.48 Million |
|
ROYAL ROAD MIN.
F:RLU
|
Germany | €307.34K |
|
Subur Tiasa Holdings Bhd
KLSE:6904
|
Malaysia | RM729.45 Million |
|
Kekrops S.A.
AT:KEKR
|
Greece | €5.38 Million |
|
Gyeongnam Steel Co. Ltd
KQ:039240
|
Korea | ₩45.20 Billion |
|
Vate Technology Co Ltd
TWO:5344
|
Taiwan | NT$103.01 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Eyepoint Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EYPT asset base.
Liquidity & Leverage Metrics
Eyepoint Pharmaceuticals Inc Total Liabilities Ratios Explained
Eyepoint Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eyepoint Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eyepoint Pharmaceuticals Inc (2000–2024)
The table below shows the annual total liabilities of Eyepoint Pharmaceuticals Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $81.96 Million | -7.76% |
| 2023-12-31 | $88.86 Million | +5.80% |
| 2022-12-31 | $83.99 Million | +6.32% |
| 2021-12-31 | $78.99 Million | +7.95% |
| 2020-12-31 | $73.18 Million | +13.20% |
| 2019-12-31 | $64.64 Million | +7.77% |
| 2018-12-31 | $59.98 Million | +1023.07% |
| 2017-12-31 | $5.34 Million | -50.26% |
| 2016-12-31 | $10.74 Million | +19.32% |
| 2015-12-31 | $9.00 Million | +16.16% |
| 2014-12-31 | $7.75 Million | -9.38% |
| 2013-12-31 | $8.55 Million | +22.81% |
| 2012-12-31 | $6.96 Million | -28.09% |
| 2011-12-31 | $9.68 Million | -2.94% |
| 2010-12-31 | $9.97 Million | -26.47% |
| 2009-12-31 | $13.56 Million | -22.23% |
| 2008-12-31 | $17.44 Million | -13.71% |
| 2007-12-31 | $20.21 Million | -35.63% |
| 2006-12-31 | $31.40 Million | +1919.22% |
| 2005-12-31 | $1.56 Million | 0.00% |
| 2004-12-31 | $1.56 Million | +15.46% |
| 2003-12-31 | $1.35 Million | +128.90% |
| 2002-12-31 | $588.38K | +303.71% |
| 2000-12-31 | $145.74K | -- |
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more